Ma’an Muhsin - Publications, H-index & Citations

Back

Ma’an Muhsin

Arrowhead Pharmaceuticals

4H-index

26Paper Count

308Citation Count

Published Papers 7

Publication Date

Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial

The Lancet Diabetes & Endocrinology

IF41.8

2025-12-18

PREAI

Frederick J Raal; Jean Bergeron; Daniel Gaudet; Robert S Rosenson; David R Sullivan; Traci Turner; Robert A Hegele; Christie M Ballantyne; Joshua W Knowles; Nicholas J Leeper; Ira J Goldberg; Rong Zhou; Ma'an Muhsin; Jennifer Hellawell; James Hamilton; Gerald F Watts

Save

Course of Pregnancy in a Woman With Familial Chylomicronemia Syndrome Treated With Plozasiran, a Small Interfering RNA Against ApoC3

JIMD Reports

IF1.8

2025-12-04

OAAI

Larouche, Miriam; Brisson, Diane; Roy, Nathalie; Grenon, Claudy; Poirier, Paul; Muhsin, Ma'an; Gaudet, Daniel

Save

Safety and efficacy of zodasiran, a hepatic sirna targeting angptl3, in mixed hyperlipidemia patients: 2 year open label extension (OLE) results from ARCHES-2

European Heart Journal

IF35.6

2025-11-05

PREAI

R S Rosenson; D Gaudet; R A Hegele; C M Ballantyne; S J Nicholls; K Lucas; J Hellawell; R Fu; M Muhsin; N J Leeper; G Watts

Save

A randomized, placebo-controlled phase 3 study of plozasiran in patients with familial chylomicronemia syndrome: PALISADE - 1 year open label extension

European Heart Journal

IF35.6

2025-11-05

PREAI

G Watts; R S Rosenson; R A Hegele; I J Goldberg; A Gallo; A Mertens; A Baass; R Fu; M Muhsin; N Leeper; J Hellawell; D Gaudet

Save

Plozasiran and Triglyceride Levels in Hypertriglyceridemia: Long-Term Efficacy and Safety Data From Subjects in an Open-Label Extension Trial

CIRCULATION

IF38.6

2024-11-12

PREAI

Ballantyne, Christie; Watts, Gerald; Rosenson, Robert; Vasas, Szilard; Pall, Denes; Clifton, Peter; Nicholls, Stephen; Azizad, Masoud; Fu, Ran; Muhsin, Maan; Melquist, Stacey; Hellawell, Jennifer; Gaudet, Daniel

Save

Rationale and design of the SHASTA-3 and SHASTA-4 studies: randomized, double-blind, placebo-controlled, phase 3 studies of plozasiran in patients with severe hypertriglyceridemia

EUROPEAN HEART JOURNAL

IF35.6

2024-10-28

PREAI

Gaudet, D. G.; Rosenson, R. S.; Hegele, R. A.; Nicholls, S. J.; Modesto, K.; Fu, R.; Muhsin, M.; Hellawell, J.; Ballantyne, C.

Save

Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia

NEW ENGLAND JOURNAL OF MEDICINE

IF78.5

2024-09-12

PREAI

Rosenson, Robert S.; Gaudet, Daniel; Hegele, Robert A.; Ballantyne, Christie M.; Nicholls, Stephen J.; Lucas, Kathryn J.; San Martin, Javier; Zhou, Rong; Muhsin, Ma'an; Chang, Ting; Hellawell, Jennifer; Watts, Gerald F.

Save

Research Directions